Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
Abstract Background For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine (pharmaceutical grade heroin). While th...
Saved in:
Main Authors: | Heather Palis (Author), Scott MacDonald (Author), Jennifer Jun (Author), Eugenia Oviedo-Joekes (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment
by: Heather Palis, et al.
Published: (2021) -
Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
by: Scott Beaumont, et al.
Published: (2024) -
Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
by: Kirsten Marchand, et al.
Published: (2020) -
Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder
by: Heather Palis, et al.
Published: (2017) -
Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
by: Eugenia Oviedo-Joekes, et al.
Published: (2021)